147 related articles for article (PubMed ID: 24900200)
1. Optimization of an albumin-binding prodrug of Doxorubicin that is cleaved by prostate-specific antigen.
Elsadek B; Graeser R; Warnecke A; Unger C; Saleem T; El-Melegy N; Madkor H; Kratz F
ACS Med Chem Lett; 2010 Aug; 1(5):234-8. PubMed ID: 24900200
[TBL] [Abstract][Full Text] [Related]
2. Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study.
Elsadek B; Graeser R; Esser N; Schäfer-Obodozie C; Abu Ajaj K; Unger C; Warnecke A; Saleem T; El-Melegy N; Madkor H; Kratz F
Eur J Cancer; 2010 Dec; 46(18):3434-44. PubMed ID: 20933385
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP).
Graeser R; Chung DE; Esser N; Moor S; Schächtele C; Unger C; Kratz F
Int J Cancer; 2008 Mar; 122(5):1145-54. PubMed ID: 17973264
[TBL] [Abstract][Full Text] [Related]
4. In vivo evaluation of a novel albumin-binding prodrug of doxorubicin in an orthotopic mouse model of prostate cancer (LNCaP).
Elsadek B; Graeser R; Esser N; Schäfer-Obodozie C; Tsurumi C; Abu Ajaj K; Warnecke A; Unger C; Saleem T; Kratz F
Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):14-21. PubMed ID: 21042336
[TBL] [Abstract][Full Text] [Related]
5. Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen.
Kratz F; Mansour A; Soltau J; Warnecke A; Fichtner I; Unger C; Drevs J
Arch Pharm (Weinheim); 2005 Oct; 338(10):462-72. PubMed ID: 16211657
[TBL] [Abstract][Full Text] [Related]
6. Screening for new peptide substrates for the development of albumin binding anticancer pro-drugs that are cleaved by prostate-specific antigen (PSA) to improve the anti tumor efficacy.
Elsadek BEM; Hassan MH
Biochem Biophys Rep; 2021 Jul; 26():100966. PubMed ID: 33718631
[TBL] [Abstract][Full Text] [Related]
7. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
[TBL] [Abstract][Full Text] [Related]
8. Anticancer activities of emetine prodrugs that are proteolytically activated by the prostate specific antigen (PSA) and evaluation of in vivo toxicity of emetine derivatives.
Akinboye ES; Rosen MD; Bakare O; Denmeade SR
Bioorg Med Chem; 2017 Dec; 25(24):6707-6717. PubMed ID: 29153549
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B.
Abu Ajaj K; Graeser R; Fichtner I; Kratz F
Cancer Chemother Pharmacol; 2009 Jul; 64(2):413-8. PubMed ID: 19229536
[TBL] [Abstract][Full Text] [Related]
10. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
[TBL] [Abstract][Full Text] [Related]
11. Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen.
Denmeade SR; Nagy A; Gao J; Lilja H; Schally AV; Isaacs JT
Cancer Res; 1998 Jun; 58(12):2537-40. PubMed ID: 9635575
[TBL] [Abstract][Full Text] [Related]
12. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin.
Abu Ajaj K; Graeser R; Kratz F
Breast Cancer Res Treat; 2012 Jul; 134(1):117-29. PubMed ID: 22228402
[TBL] [Abstract][Full Text] [Related]
13. A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer.
Chandran SS; Nan A; Rosen DM; Ghandehari H; Denmeade SR
Mol Cancer Ther; 2007 Nov; 6(11):2928-37. PubMed ID: 18025277
[TBL] [Abstract][Full Text] [Related]
14. Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy.
Akinboye ES; Brennen WN; Rosen DM; Bakare O; Denmeade SR
Prostate; 2016 Jun; 76(8):703-14. PubMed ID: 26835873
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
Denmeade SR; Jakobsen CM; Janssen S; Khan SR; Garrett ES; Lilja H; Christensen SB; Isaacs JT
J Natl Cancer Inst; 2003 Jul; 95(13):990-1000. PubMed ID: 12837835
[TBL] [Abstract][Full Text] [Related]
16. Development of dual-acting prodrugs for circumventing multidrug resistance.
Abu Ajaj K; Kratz F
Bioorg Med Chem Lett; 2009 Feb; 19(3):995-1000. PubMed ID: 19131246
[TBL] [Abstract][Full Text] [Related]
17. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2.
Mansour AM; Drevs J; Esser N; Hamada FM; Badary OA; Unger C; Fichtner I; Kratz F
Cancer Res; 2003 Jul; 63(14):4062-6. PubMed ID: 12874007
[TBL] [Abstract][Full Text] [Related]
18. In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts.
Khan SR; Denmeade SR
Prostate; 2000 Sep; 45(1):80-3. PubMed ID: 10960846
[TBL] [Abstract][Full Text] [Related]
19. Peptide conjugates of 4-aminocyclophosphamide as prodrugs of phosphoramide mustard for selective activation by prostate-specific antigen (PSA).
Jiang Y; Hu L
Bioorg Med Chem; 2013 Dec; 21(23):7507-14. PubMed ID: 24139844
[TBL] [Abstract][Full Text] [Related]
20. Targeted prodrug approaches for hormone refractory prostate cancer.
Aloysius H; Hu L
Med Res Rev; 2015 May; 35(3):554-85. PubMed ID: 25529338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
